MedTrace Logo

MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

NCT06392282 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2024-04-30

No results posted yet for this study

Summary

We will access the efficacy of MV-140 immunotherapy in the prevention of recurrent urinary tract infections in a cohort of Portuguese patients.

Conditions

Interventions

DRUG

MV-140

MV-140 use - sublingual spray approved for recurrent UTI prevention

Sponsors & Collaborators

  • Unidade Local de Saúde Santa Maria

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06392282 on ClinicalTrials.gov